Canada’s main stock index has had a dynamic week, buoyed by global trade developments and investor optimism. Monday saw a significant rally after the United States and China agreed to temporarily reduce reciprocal tariffs, easing fears of a full-scale trade war. This momentum carried into Tuesday, with the TSX edging higher despite a cooling Wall Street. By Wednesday, trading settled into a quieter rhythm as market participants digested earlier gains and awaited further trade news.
What the “Buzz”
Our Bullboards have up to 2 million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.
Get “Buzz on the Bullboards” delivered to your inbox every third Thursday!
Buzz on the Bullboards | Sign Up Here
This week also marks the heart of quarterly earnings season, a critical period when companies disclose their financial and operational performance. For investors, these reports offer valuable insights into corporate health and future prospects. Among the many companies reporting, three TSX-listed names have stood out.
A cannabis leader on the rise
Organigram Holdings Inc. (TSX:OGI, Forum), a leading licensed cannabis producer, delivered a robust Q2 fiscal 2025 earnings report, showcasing impressive growth across key financial metrics:
Financial highlights
- Gross revenue: Soared 79% to $102.8 million.
- Net revenue: Increased 74% to $65.6 million.
- International revenue: Jumped 177% to $6.1 million.
- Adjusted gross margin: Rose to $21.9 million (33%).
- Adjusted EBITDA: Rebounded to $4.9 million from a loss of $1.0 million.
- Cash position: Strong at $83.4 million with minimal debt.
Operational achievements
Organigram maintains the #1 market share in Canada, leading in vapes, pre-rolls, milled flower, hash, and CBD gummies. The integration of Motif is expected to yield $15 million in annual cost synergies, exceeding initial projections. The acquisition of Collective Project Ltd. also marks a strategic entry into the cannabis beverage market across North America.
Global expansion
With $6.1 million in international sales this quarter, Organigram is expanding its footprint through partnerships in Germany, the U.K., and Australia, with more global opportunities on the horizon.
Advancing cancer immunotherapy
Oncolytics Biotech Inc. (TSX:ONC, Forum), a clinical-stage biotech firm, continues to make strides in oncology with its proprietary immunotherapy, pelareorep.
Q1 2025 financial overview
- Cash & Equivalents: $15.3 million, supporting operations through Q3 2025.
- Net Loss: Narrowed slightly to $6.7 million.
- R&D Expenses: Declined to $4.1 million, reflecting lower trial costs.
- G&A Expenses: Held steady at $3.0 million.
Clinical progress
The company will present new data at the ASCO Annual Meeting, highlighting pelareorep’s immune-activating potential in pancreatic cancer. Updated results from the GOBLET study showed a 33% objective response rate in patients with advanced squamous cell anal carcinoma, including a complete response lasting over 15 months.
Upcoming milestones
- Q2 2025: Translational data from pancreatic cancer cohort.
- H1 2026: Initial efficacy results from newly diagnosed metastatic pancreatic cancer cohort.
These developments position Oncolytics as a compelling biotech play with potential for breakthrough therapies in hard-to-treat cancers.
A new energy powerhouse
Whitecap Resources Inc. (TSX:WCP, Forum) has completed its transformative merger with Veren Inc., creating one of Canada’s largest oil and gas producers.
Strategic highlights
- Now the 7th largest oil and gas and 5th largest natural gas producer in Canada.
- Largest landholder in Alberta’s Montney and Duvernay formations.
- Strong presence in Saskatchewan’s light oil sector.
Leadership and governance
The combined entity will be led by Whitecap’s management team and a refreshed board of directors, blending leadership from both companies. This strategic alignment is expected to enhance operational efficiency and shareholder value.
2025 guidance
- Average Production: Raised to 295,000–300,000 boe/d (63% liquids).
- H2 2025 Forecast: 363,000–368,000 boe/d on $1.1 billion in capex.
- Annual Capex: Approximately $2.0 billion.
With a deep inventory of premium drilling opportunities and a focus on sustainable growth, Whitecap is well-positioned to deliver long-term value.
A season of opportunity
As earnings season unfolds, investors are reminded of the importance of staying informed and agile. Whether it’s Organigram’s international cannabis expansion, Oncolytics’ promising cancer therapies, or Whitecap’s energy sector consolidation, these TSX-listed companies exemplify the diverse opportunities available in Canada’s capital markets.
Now is the time to dig deeper, analyze performance trends, and align your portfolio with the evolving market landscape.
Get “Buzz on the Bullboards” delivered to your inbox every third Thursday!
Buzz on the Bullboards | Sign Up HereFor previous editions of Buzz on the Bullboards, click here.
Join the discussion: Find out what everybody’s saying about these stock on Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
